$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000114420416100445 Filed on May 10, 2016

Income Statement

Concept	2016 Q1	2015 Q2	2015 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$980.0K	$1.050M	$600.0K
YoY Change	63.33%	-33.96%	-1.64%
% of Gross Profit
Research & Development	$1.067M	$1.390M	$546.5K
YoY Change	95.35%	-36.82%	-12.67%
% of Gross Profit
Depreciation & Amortization	$163.5K	$140.0K	$51.33K
YoY Change	218.54%	180.0%	2.66%
% of Gross Profit
Operating Expenses	$1.067M	$2.440M	$1.123M
YoY Change	-4.91%	-35.62%	-8.98%
Operating Profit			-$1.123M
YoY Change			-8.98%
Interest Expense	$301.1K	$1.830M	$1.920M
YoY Change	-84.32%	-230.71%	-29.55%
% of Operating Profit
Other Income/Expense, Net	-$2.943M	-$310.0K	$871.6K
YoY Change	-437.7%	106.67%	-65.92%
Pretax Income	-$4.992M	-$920.0K	-$251.0K
YoY Change	1888.57%	-82.77%	-118.96%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.992M	-$920.0K	-$251.0K
YoY Change	1888.57%	-82.77%	-118.96%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.09		$0.00
Diluted Earnings Per Share	-$0.09	-$321.7K	-$0.02
COMMON SHARES
Basic Shares Outstanding	57.84M shares	57.15M shares	56.94M shares
Diluted Shares Outstanding	57.84M shares		59.61M shares

Balance Sheet

Concept	2016 Q1	2015 Q2	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$25.60M	$31.47M	$33.92M
YoY Change	-24.53%	-14.25%	1.95%
Cash & Equivalents	$25.60M	$31.47M	$33.92M
Short-Term Investments
Other Short-Term Assets	$310.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Inventory
Prepaid Expenses	$314.5K	$214.4K	$308.6K
Receivables
Other Receivables
Total Short-Term Assets	$25.91M	$31.68M	$34.29M
YoY Change	-24.45%	-14.27%	-0.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.90M	$11.96M	$10.91M
YoY Change	9.09%	117.63%	177.16%
Goodwill
YoY Change
Intangibles		$399.7K	$401.8K
YoY Change		-2.09%	-2.11%
Long-Term Investments
YoY Change
Other Assets	$120.0K	$140.0K	$0.00
YoY Change		-86.0%	-100.0%
Total Long-Term Assets	$12.41M	$12.50M	$11.31M
YoY Change	9.71%	81.1%	78.21%
TOTAL ASSETS
Total Short-Term Assets	$25.91M	$31.68M	$34.29M
Total Long-Term Assets	$12.41M	$12.50M	$11.31M
Total Assets	$38.32M	$44.19M	$45.60M
YoY Change	-15.98%	0.75%	11.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$450.0K	$410.0K	$20.00K
YoY Change	2150.0%	-4.65%	-98.0%
Accrued Expenses	$78.37K	$28.52K	$125.1K
YoY Change	-37.33%	-68.95%	-39.62%
Deferred Revenue
YoY Change
Short-Term Debt	$5.270M	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.271M	$0.00
YoY Change
Total Short-Term Liabilities	$6.619M	$600.9K	$523.4K
YoY Change	1164.59%	16.06%	-56.67%
LONG-TERM LIABILITIES
Long-Term Debt	$2.960M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$4.760M	$4.620M	$6.350M
YoY Change	-25.04%	-57.77%	66.23%
Total Long-Term Liabilities	$7.716M	$11.80M	$13.22M
YoY Change	-41.62%	-40.92%	12.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.619M	$600.9K	$523.4K
Total Long-Term Liabilities	$7.716M	$11.80M	$13.22M
Total Liabilities	$14.34M	$12.40M	$13.74M
YoY Change	4.32%	-39.48%	5.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$63.17M	-$54.10M	-$53.18M
YoY Change	18.79%	4.24%	18.44%
Common Stock		$57.24K	$57.15K
YoY Change		4.8%	4.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.98M	$31.79M	$31.86M
YoY Change
Total Liabilities & Shareholders Equity	$38.32M	$44.19M	$45.60M
YoY Change	-15.97%	0.75%	11.36%

Cashflow Statement

Concept	2016 Q1	2015 Q2	2015 Q1
OPERATING ACTIVITIES
Net Income	-$4.992M	-$920.0K	-$251.0K
YoY Change	1888.57%	-82.77%	-118.96%
Depreciation, Depletion And Amortization	$163.5K	$140.0K	$51.33K
YoY Change	218.54%	180.0%	2.66%
Cash From Operating Activities	-$2.580M	-$1.250M	-$2.090M
YoY Change	23.44%	31.58%	12.37%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	-$1.200M	-$250.0K
YoY Change	-76.0%	-25.47%	-80.16%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$1.000M
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$60.00K	-$1.200M	$750.0K
YoY Change	-108.0%	96.72%	-159.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change		-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-2.580M	-1.250M	-2.090M
Cash From Investing Activities	-60.00K	-1.200M	750.0K
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-2.640M	-2.450M	-1.340M
YoY Change	97.01%	-171.22%	-108.21%
FREE CASH FLOW
Cash From Operating Activities	-$2.580M	-$1.250M	-$2.090M
Capital Expenditures	-$60.00K	-$1.200M	-$250.0K
Free Cash Flow	-$2.520M	-$50.00K	-$1.840M
YoY Change	36.96%	-107.58%	206.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-150000	USD
CY2015Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11800327	USD
CY2015Q2	us-gaap	Liabilities Liabilities	12401222	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78369	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28515	USD
CY2015Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	316196	USD
CY2016Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7716449	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1280461	USD
CY2015Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	214425	USD
	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	547946	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2186078	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1280461	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	89517	USD
CY2015Q2	us-gaap	Assets Assets	44187089	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11897918	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11962648	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1690724	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1534203	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13588642	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	65419	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	59217	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13496851	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	31682173	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25596376	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31467748	USD
CY2015Q2	us-gaap	Interest Payable Current InterestPayableCurrent	166667	USD
CY2016Q1	us-gaap	Interest Payable Current InterestPayableCurrent	166668	USD
CY2015Q2	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	333333	USD
CY2016Q1	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	208332	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87093276	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85824613	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	314489	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	25910865	USD
CY2016Q1	us-gaap	Assets Assets	38317508	USD
CY2016Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	71860	USD
CY2016Q1	us-gaap	Liabilities Liabilities	14335690	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63173488	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	23981818	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2936510	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6363578	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10002	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	6463095	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3179927	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2274310	USD
	us-gaap	Interest Expense InterestExpense	2412712	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56356105	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59022772	shares
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	980731	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	576173	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	1122637	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2710338	USD
	us-gaap	Operating Expenses OperatingExpenses	4460388	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4460388	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	860454	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-915938	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9073916	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9073916	USD
	us-gaap	Interest Expense InterestExpense	791115	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57565406	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57565406	shares
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6619241	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	600895	USD
CY2015Q2	nnvc	Service Agreements ServiceAgreements	142531	USD
CY2016Q1	nnvc	Service Agreements ServiceAgreements	108951	USD
	us-gaap	Operating Expenses OperatingExpenses	6363578	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1067495	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	546464	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	39116	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35009	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	301115	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	1920268	USD
CY2016Q1	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	362993	USD
CY2015Q1	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	297276	USD
CY2016Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2318453	USD
CY2015Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3054154	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2943445	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	871619	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4991671	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-251018	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-4991671	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-251018	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57836770	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56941122	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57836770	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59607788	shares
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	43378	USD
	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust	29422	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3300	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	106000	USD
	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	493334	USD
	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	33750	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	205837	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	547946	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	116110	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	143050	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	52130	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	29422	USD
	us-gaap	Depreciation Depreciation	153996	USD
	us-gaap	Depreciation Depreciation	488997	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	6453	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	6202	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	6463095	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	200515	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4956633	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5447105	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6743297	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2777488	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5871372	USD
	us-gaap	Interest Paid InterestPaid	791115	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1152297	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1046663	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	860454	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-27341	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36696892	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33919404	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	49854	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	33215	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-353071	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	64669	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-115555	USD
	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	313	USD
	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-493334	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-1502869	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-375000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-17657	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-125000	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-915938	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	100064	USD
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	332476	USD
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2000-07-25
	us-gaap	Business Acquisition Date Of Acquisition Agreement1 BusinessAcquisitionDateOfAcquisitionAgreement1	2005-05-12
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6495242	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6599552	shares
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	nnvc	Convertible Debentures Shares Reserved For Future Issuance ConvertibleDebenturesSharesReservedForFutureIssuance	571433	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2666667	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2666667	shares
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.09
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.02
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.16
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.07
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4991671	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-947121	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9073916	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4021023	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4991671	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-251018	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9073916	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1280461	USD
CY2016Q1	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2015Q1	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-696103	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-2740562	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.09
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.00
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.16
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.02
CY2015Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2016Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2015Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7905938	USD
CY2016Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7996402	USD
CY2015Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	65241	USD
CY2016Q1	nnvc	Office Equipment Gross OfficeEquipmentGross	76056	USD
CY2015Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1400	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2479935	shares
CY2016Q1	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5250577	USD
CY2016Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2015Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5264272	USD
CY2016Q1	us-gaap	Land Land	260000	USD
CY2015Q2	us-gaap	Land Land	260000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	163511	USD
CY2015Q1	us-gaap	Depreciation Depreciation	51332	USD
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	332476	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	399737	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	393535	USD
	nnvc	Share Based Compensation Arrangement By Share Based Payment Award Voting Rights Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage	0.0536	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2013Q3	nnvc	Warrants Issued WarrantsIssued	2945428	shares
CY2014Q1	nnvc	Warrants Issued WarrantsIssued	2479935	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2810071	shares
CY2016Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5425222	shares
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	0	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	78255	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	26085	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	0	USD
CY2016Q1	us-gaap	Security Deposit SecurityDeposit	6239	USD
CY2015Q2	us-gaap	Security Deposit SecurityDeposit	0	USD
CY2016Q1	us-gaap	Other Assets OtherAssets	115190	USD
CY2015Q2	us-gaap	Other Assets OtherAssets	142531	USD
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57973199	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57973199	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57242070	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57242070	shares
	nnvc	Adjustments To Additional Paid In Capital Warrant Issued For Debenture Interest AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForDebentureInterest	56115	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	56115	USD
	us-gaap	Proceeds From Collection Of Advance To Affiliate ProceedsFromCollectionOfAdvanceToAffiliate	0	USD
	us-gaap	Proceeds From Collection Of Advance To Affiliate ProceedsFromCollectionOfAdvanceToAffiliate	1000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-424267	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4564152	USD
	nnvc	Issuance Of Series C Debenture For Deposit Received IssuanceOfSeriesCDebentureForDepositReceived	5000000	USD
	nnvc	Bifurccation Of Embedded Derivative BifurccationOfEmbeddedDerivative	1879428	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Note 1 - Organization and Nature of Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">NanoViricides, Inc. was incorporated under the laws of the State of Colorado on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> July 25, 2000</font> as Edot-com.com, Inc<b>.</b> which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font> shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of the Company by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> NanoViricides,  Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and e-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 15, 2010 the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a one-time licensing fee equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.</font>  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The 2,000,000 shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iii), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
	nnvc	Lab Supplies And Chemicals Fees LabSuppliesAndChemicalsFees	25000	USD
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2013Q3	nnvc	Warrant Expiration Term WarrantExpirationTerm	P5Y
CY2014Q1	nnvc	Warrant Expiration Term WarrantExpirationTerm	P5Y
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.25
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.05
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	424267	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5564152	USD
CY2016Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	5271087	USD
CY2015Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2016Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	650392	USD
CY2015Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Colorado
	us-gaap	Business Acquisition Name Of Acquired Entity BusinessAcquisitionNameOfAcquiredEntity	Edot-com.com, Inc.
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i><u>Reclassification</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none"> Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results or operations.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	571433	shares
CY2016Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.50
CY2016Q1	nnvc	Warrant Expiration Term WarrantExpirationTerm	P3Y
CY2016Q1	nnvc	Adjustments To Additional Paid In Capital Warrant Issued For Debenture Interest AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForDebentureInterest	56115	USD
CY2016Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	375000	USD
CY2015Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	500000	USD
	nnvc	Issuance Of Series C Debenture For Deposit Received IssuanceOfSeriesCDebentureForDepositReceived	0	USD
	nnvc	Bifurccation Of Embedded Derivative BifurccationOfEmbeddedDerivative	0	USD

Files In Submission

Name	View Source	Status
0001144204-16-100445-index-headers.html	Edgar Link	pending
0001144204-16-100445-index.html	Edgar Link	pending
0001144204-16-100445.txt	Edgar Link	pending
0001144204-16-100445-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nnvc-20160331.xml	Edgar Link	completed
nnvc-20160331.xsd	Edgar Link	pending
nnvc-20160331_cal.xml	Edgar Link	unprocessable
nnvc-20160331_def.xml	Edgar Link	unprocessable
nnvc-20160331_lab.xml	Edgar Link	unprocessable
nnvc-20160331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v438438_10q.htm	Edgar Link	pending
v438438_ex31-1.htm	Edgar Link	pending
v438438_ex31-2.htm	Edgar Link	pending
v438438_ex32-1.htm	Edgar Link	pending
v438438_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2016 Q1 Form 10-Q Financial Statement

#000114420416100445 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2016 Q1 Form 10-Q Financial Statement

#000114420416100445 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc